'Invitae Hires FTI, Kirkland & Ellis To Advise Options To Address $1.5B Of Debt As Company Prepares For Bankruptcy; Co Has Been Selling Assets To Shore Up Liquidity As Business Tanks' - WSJ

2/5/24 11:12:37 AM ET

Medical Specialities

Health Care

Get the next $NVTA alert in real time by email

https://www.wsj.com/articles/softbank-backed-medical-genetics-company-invitae-prepares-for-bankruptcy-d468f120?st=02yzwzf1bnabmx0&mod=googlenewsfeed

Invitae, a medical genetics company that received backing from SoftBank Group at the height of the pandemic has hired restructuring advisers and is preparing to file for bankruptcy within weeks, according to people familiar with the matter.

The company is working with FTI Consulting and law firm Kirkland & Ellis to explore strategic options, including bankruptcy, to address $1.5 billion in debt on its balance sheet, the people said.

Get the next $NVTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVTA

Date	Price Target	Rating	Analyst
7/5/2023		Underweight	JP Morgan
5/15/2023		Mkt Perform → Underperform	Raymond James
1/31/2023	$2.00	Neutral → Sell	Goldman
8/25/2022	$1.00	Underperform	Credit Suisse
8/10/2022		Neutral → Underweight	JP Morgan
7/26/2022	$8.00 → $2.50	Outperform → Market Perform	Cowen
7/21/2022		Outperform → Mkt Perform	Raymond James
7/20/2022		Buy → Neutral	Ladenburg Thalmann

More analyst ratings

$NVTA
Financials

Live finance-specific insights

Natera Acquires Reproductive Health Assets from Invitae
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits. Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera. "We are committed to providing excellent service, and we look forward to the o
1/22/24 7:00:00 AM ET
$NTRA
$NVTA
Medical Specialities
Health Care
Invitae Reports Second Quarter 2023 Financial Results
– Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year – – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res
8/8/23 4:01:00 PM ET
$NVTA
Medical Specialities
Health Care
Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">
7/26/23 4:01:00 PM ET
$NVTA
Medical Specialities
Health Care

$NVTA
Market Insights

Live Market Insights

Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Thursday, Labcorp (NYSE:LH) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%. The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign currency translation of 0.5%. The 2.3% increase in organic revenue was driven by a 4.2% increase in the company’s organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing). The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago. Diagnostics Laboratories revenue for the quarter was $2.48 billion, an increase of 4.1%. Total volume
4/25/24 3:04:27 PM ET
$LH
$NVTA
Medical Specialities
Health Care
Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024
4/25/24 3:28:40 AM ET
$LH
$NVTA
Medical Specialities
Health Care
Softbank-Backed Cohesity To Acquire Veritas Data Security Unit For $3B: Report
SoftBank Group Corp (OTC:SFTBY) (OTC:SFTBF) backed Cohesity has agreed to the acquisition of the data protection business of Veritas Technologies LLC. The deal is valued at $3 billion, creating a combined entity worth $7 billion. What Happened: Cohesity, a U.S.-based data security software company, is set to acquire the data protection business of Veritas, a subsidiary of Carlyle Group Inc (NASDAQ:CG). The deal, comprising cash and stock, is expected to be finalized by the end of the year, as per source-based report by Reuters. The acquisition is anticipated to bolster Cohesity’s growth margins and facilitate its expansion into international markets. The combined annual revenue of the
2/8/24 4:34:57 AM ET
$ARM
$CG
$NVTA
Semiconductors
Technology
Investment Managers
Finance

Labcorp Announces Winning Bid for Select Assets of Invitae
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.
4/24/24 9:27:00 PM ET
$LH
$NVTA
Medical Specialities
Health Care
Invitae Enters into Agreement with Labcorp for Sale of Business
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis
4/24/24 9:19:00 PM ET
$LH
$NVTA
Medical Specialities
Health Care
Invitae Publishes its Environmental, Social and Governance (ESG) Report
– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c
4/22/24 12:43:00 PM ET
$NVTA
Medical Specialities
Health Care

$NVTA
Leadership Updates

Live Leadership Updates

Aranscia Acquires YouScript from Invitae
Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc
11/15/23 4:35:00 PM ET
$NVTA
Medical Specialities
Health Care
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu
9/25/23 4:30:00 PM ET
$NVTA
Medical Specialities
Health Care
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
– Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth – SAN FRANCISCO, Aug. 28, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of
8/28/23 4:02:00 PM ET
$NVTA
Medical Specialities
Health Care

'Invitae Hires FTI, Kirkland & Ellis To Advise Options To Address $1.5B Of Debt As Company Prepares For Bankruptcy; Co Has Been Selling Assets To Shore Up Liquidity As Business Tanks' - WSJ

Chat with this insight

Recent Analyst Ratings for $NVTA

$NVTA SEC Filings

SEC Form 25-NSE filed by Invitae Corporation

Invitae Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Invitae Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NVTA Financials

Live finance-specific insights

Natera Acquires Reproductive Health Assets from Invitae

Invitae Reports Second Quarter 2023 Financial Results

Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

$NVTA Market Insights

Live Market Insights

Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal

Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases

Softbank-Backed Cohesity To Acquire Veritas Data Security Unit For $3B: Report

$NVTA Press Releases

Fastest customizable press release news feed in the world

$NVTA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Labcorp Announces Winning Bid for Select Assets of Invitae

Invitae Enters into Agreement with Labcorp for Sale of Business

Invitae Publishes its Environmental, Social and Governance (ESG) Report

JP Morgan resumed coverage on Invitae

Invitae downgraded by Raymond James

Invitae downgraded by Goldman with a new price target

$NVTA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Nussbaum Robert L covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 3% to 551,941 units (SEC Form 4)

Brida Thomas covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 2% to 916,183 units (SEC Form 4)

Sholehvar David was granted 850,000 shares (SEC Form 4)

$NVTA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

$NVTA Leadership Updates

Live Leadership Updates

Aranscia Acquires YouScript from Invitae

Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

Recent Analyst Ratings for
$NVTA

$NVTA
SEC Filings

$NVTA
Financials

$NVTA
Market Insights

$NVTA
Press Releases

$NVTA
Analyst Ratings

$NVTA
Insider Trading

$NVTA
Large Ownership Changes

$NVTA
Leadership Updates